Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

MapLight reports $463.4m cash as schizophrenia Phase 3 prep begins; Alzheimer's psychosis readout slips to 2028

The US neuropsychiatry biotech is preparing a second late-stage schizophrenia study and says it may seek partners or other funding for its autism candidate.

16 Nov 2026 · MapLight Therapeutics, Inc. MPLT · Company news

MapLight Therapeutics said on 16 November 2026, alongside third-quarter results, that it has begun start-up work on ZEPHYR-2, a confirmatory Phase 3 study of ML-007C-MA in schizophrenia. The company reported cash of $463.4 million at the end of the quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): MapLight Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →